Biolojic Design, Ltd. is a pioneering biopharmaceutical company focused on developing innovative human antibody-based therapeutics aimed at treating cancer and other diseases. Founded in 2009, this Israeli startup leverages cutting-edge biotechnology and AI to target functional epitopes, addressing challenges where existing technologies fall short.
Having attracted a $3.95M late-stage venture capital investment in early 2021, Biolojic Design stands out for its robust potential in the biotechnology and pharmaceutical industries. Key investors such as OurCrowd, aMoon, and Winnovation uphold the company's vision and revolutionary approach.
The strategic location in Israel, a hub for innovation, further strengthens its competitive edge. In summary, Biolojic Design represents a compelling opportunity for investors interested in disruptive advancements in antibody-based therapies, with applications extending beyond oncology to diverse disease categories.